Bayer seeking approval of OTC Pravachol version

Share this article:

German drugmaker Bayer is in talks with the FDA about marketing a low-dose version of the cholesterol drug Pravachol to consumers in the US without a prescription, Bloomberg News reports.

“The most recent dialogues we've had with the FDA in the spring are the most encouraging we've seen thus far and we'll continue those,” Gary Balkema, head of Bayer’s consumer unit, told investors during a conference held last week.

Bayer owns the rights to the US consumer version of Pravachol, purchased from Bristol-Myers Squibb, and said it plans to shoulder the cost of the product’s development.

Bayer is planning to succeed where Merck and Bristol-Myers Squibb have failed in the past.

In 2000, the FDA rejected requests Merck, which sells Mevacor and Bristol-Myers Squibb which owns Pravachol. Both companies sought to sell low-dose OTC versions of their products. In 2005, the agency rejected a second try by Merck and Johnson & Johnson saying research did not show an OTC version of Mevacor would be used safely.

Meanwhile, Merck’s statin Zocor has been available in the UK since 2004 with pharmacists having the ability to decide whether the consumer gets the medicine.

Approximately $22 billion is spent globally each year on cholesterol lowering medicines.

Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.